文献速递结核与非结核分枝杆菌艾滋病与性传播感染

高负担地区异烟肼联合利福喷丁与单用异烟肼预防结核治疗的成本效果比较

Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings.
PubMed 文献 · Clin Infect Dis · 2018-01-01

该研究采用马尔可夫状态转移模型,以乌干达一家HIV诊所1000例患者为例,在高负担地区比较每周一次利福喷丁联合异烟肼3个月方案(3HP)与至少6个月每日异烟肼预防治疗(IPT)的成本效果。结果显示3HP较IPT每1000人避免9例结核和1例死亡,每避免一个伤残调整生命年(DALY)花费9402美元;成本效果取决于利福喷丁价格、3HP完成率和潜伏结核患病率。

要点

  • 3HP较IPT每1000人避免9例结核和1例死亡,每避免一个DALY花费9402美元。
  • 成本效果取决于利福喷丁价格、3HP完成率和潜伏结核患病率。
  • 支付意愿为每DALY 1000美元时,3HP可能具成本效果仅当利福喷丁价格约降至每疗程20美元且完成率达85%。

核心结论

  • 3HP在高负担地区可能是有成本效果的IPT替代方案,但成本效果取决于利福喷丁价格、可达到的完成率和当地支付意愿。

研究设计与样本

  • 采用马尔可夫状态转移模型,以乌干达一家HIV诊所1000例患者为示例场景,估算高负担地区3HP相对于IPT的增量成本效果。

主要发现

  • 在参考场景下,每1000例接受抗逆转录病毒治疗者中,3HP较IPT估计避免9例结核和1例死亡。
  • 3HP相对于IPT每避免一个DALY花费9402美元(以2017年美元计,从医疗保健角度、20年时间范围)。

关键数值与推荐

  • 成本效果强烈取决于利福喷丁价格、3HP完成率和潜伏结核患病率。
  • 支付意愿为每DALY 1000美元时,3HP相对IPT可能具成本效果仅当利福喷丁价格大幅降低至约每疗程20美元且达到高治疗完成率(85%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A short-course regimen of 3 months of weekly rifapentine and isoniazid (3HP) has recently been recommended by the World Health Organization as an alternative to at least 6 months of daily isoniazid (isoniazid preventive therapy [IPT]) for prevention of tuberculosis (TB). The contexts in which 3HP may be cost-effective compared to IPT among people living with human immunodeficiency virus are unknown. METHODS: We used a Markov state transition model to estimate the incremental cost-effectiveness of 3HP relative to IPT in high-burden settings, using a cohort of 1000 patients in a Ugandan HIV clinic as an emblematic scenario. Cost-effectiveness was expressed as 2017 US dollars per disability-adjusted life year (DALY) averted from a healthcare perspective over a 20-year time horizon. We explored the conditions under which 3HP would be considered cost-effective relative to IPT. RESULTS: Per 1000 individuals on antiretroviral therapy in the reference scenario, treatment with 3HP rather than IPT was estimated to avert 9 cases of TB and 1 death, costing $9402 per DALY averted relative to IPT. Cost-effectiveness depended strongly on the price of rifapentine, completion of 3HP, and prevalence of latent TB. At a willingness to pay of $1000 per DALY averted, 3HP is likely to be cost-effective relative to IPT only if the price of rifapentine can be greatly reduced (to approximately $20 per course) and high treatment completion (85%) can be achieved. CONCLUSIONS: 3HP may be a cost-effective alternative to IPT in high-burden settings, but cost-effectiveness depends on the price of rifapentine, achievable completion rates, and local willingness to pay.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Johnson KT, Churchyard GJ, Sohn H, et al. Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings. Clin Infect Dis. 2018. PMID: 29617965. doi:10.1093/cid/ciy230

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。